Topics:
Hematologic Malignancies • Pediatric Oncology • Bone Marrow Transplant • Leukemia • AML • ALL • Hematology
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?
Answer from: at Academic Institution
There are variable practices with the use of filgrastim post-allogeneic HSCT to facilitate engraftment. Older publications linked its use to a higher incidence of acute graft versus host disease and delayed platelets recovery (Remberger et al., PMID 12838288, Ringdén et al., PMID 14691124, an...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
A word of caution regarding the use of G-CSF in the setting of using ATG for GVHD prophylaxis. We published in 2021 (Orfali et al., PMID 34507002) a multicenter retrospective analysis of the interaction between ATG and post-transplantation G-CSF on allogeneic HCT outcomes for myeloid malignancies an...